Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics (Nasdaq: MCRB) received up to $3.6 million in non-dilutive funding from CARB-X to develop and manufacture an oral liquid formulation of SER-155 for medically vulnerable patients who cannot take capsules, including intubated ICU patients.

SER-155, developed for allo-HSCT patients, showed a 77% reduction in bacterial bloodstream infections (BSIs) versus placebo in a randomized Phase 1b study and reduced systemic antibiotic use and febrile neutropenia. The company received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the clinical protocol.

Seres Therapeutics (Nasdaq: MCRB) announced new post hoc data from the SER-155 Phase 1b trial will be presented orally at IDWeek 2025 on October 20, 2025. The presentation reports differences between SER-155 and placebo in bacterial and fungal bloodstream infection (BSI) pathogens, clinical BSI outcomes, antibacterial prophylaxis use, and antimicrobial resistance patterns.

Key disclosed result: in the randomized, double-blind Phase 1b cohort, SER-155 reduced BSIs by 77% and lowered systemic antibiotic use and febrile neutropenia. The company said it received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the protocol while pursuing capital to advance SER-155 and its live biotherapeutics portfolio.

Seres Therapeutics (NASDAQ:MCRB) has received constructive FDA feedback on its Phase 2 study protocol for SER-155, a breakthrough therapy-designated treatment for preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant.

The planned Phase 2 study will be placebo-controlled with 248 participants, focusing on preventing bloodstream infections through 30 days post-transplant. An interim analysis is expected within 12 months of study initiation.

To extend its cash runway into Q2 2026, Seres is implementing cost reduction measures, including a 25% workforce reduction with severance costs of $1.0-$1.4 million. The company continues seeking capital to advance the SER-155 study and its broader portfolio.

Seres Therapeutics (Nasdaq: MCRB), a live biotherapeutics company, will participate in the H.C. Wainwright Global Investment Conference in New York City. The company's management will deliver a corporate presentation on September 8, 2025 at 3:00 p.m. ET.

A webcast replay of the presentation will be accessible on the Seres website approximately two hours after the event and will remain available for 21 days.

Seres Therapeutics (NASDAQ: MCRB) reported Q2 2025 financial results and business updates. The company submitted a Phase 2 study protocol to FDA for SER-155, targeting bloodstream infection prevention in stem cell transplant patients. The planned study will enroll 248 participants with interim analysis expected within 12 months of initiation.

Key financial highlights include a net loss of $19.9 million in Q2 2025, reduced from $26.2 million in Q2 2024. The company received a $25 million payment from Nestlé Health Science in July 2025 and expects to fund operations into Q1 2026. Management changes include the appointment of Thomas DesRosier and Marella Thorell as co-CEOs, effective August 1, 2025.

Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.

The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.

Seres Therapeutics (NASDAQ:MCRB) announced a significant leadership transition as Thomas DesRosier and Marella Thorell are appointed co-CEOs, effective July 31, 2025, following current CEO Eric Shaff's departure. Both executives will retain their existing roles as Chief Legal Officer and Chief Financial Officer, respectively.

The company is actively engaging with multiple parties for potential business development and partnerships to secure additional capital for advancing SER-155, which has received Breakthrough Therapy designation. The drug showed promising Phase 1b results with a 77% relative risk reduction in bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT).

Eric Shaff, who led Seres for a decade and achieved the first-ever FDA-approved oral microbiome therapy, will remain on the company's Board of Directors.

Seres Therapeutics (NASDAQ: MCRB) presented new exploratory biomarker data from its SER-155 Phase 1b study at the 2025 ASCO Annual Meeting. The data shows promising results for SER-155, a live biotherapeutic product designed to reduce infection risks in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT). Key findings include: - 77% relative risk reduction in bloodstream infections with SER-155 treatment - Significantly higher levels of homeostatic cytokine IL-7 compared to placebo - Higher frequency of CD4+ T cells in peripheral blood - Evidence of improved intestinal epithelial barrier integrity - Modulation of systemic inflammatory responses The company plans to submit a Phase 2 trial protocol to the FDA and is seeking partners for continued clinical development.

Seres Therapeutics (NASDAQ: MCRB) reported Q1 2025 financial results and provided updates on its lead candidate SER-155. The company plans to submit a Phase 2 study protocol to FDA for SER-155, targeting the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. Previous Phase 1b data showed a 77% relative risk reduction in bloodstream infections.

Financial highlights include net income of $32.7 million for Q1 2025, compared to a net loss of $32.9 million in Q1 2024. The company had $58.8 million in cash as of March 31, 2025, with runway into Q1 2026. A $25 million payment from Nestlé is expected in July 2025. The company recently completed a 1-for-20 reverse stock split and regained Nasdaq compliance.